Clinical Trial Update: Open-label Safety Study in Adults With ADHD [Phase 3]

View source ↗

Summary

Open-label Phase 3 safety study in adults with attention-deficit/hyperactivity disorder has completed; sponsor is Sumitomo Pharma America, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Adult Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED